Ir para o conteúdo principal

Aclaris Therapeutics (NASDAQ: ACRS) — Perfil da empresa, notícias e dados financeiros

Logo de Aclaris Therapeutics
ACRS Aclaris Therapeutics
Aclaris Therapeutics primary media
Perfil da empresa

Aclaris Therapeutics

Aclaris Therapeutics (NASDAQ:ACRS) specializes in developing novel drug candidates and therapies in dermatology and immunology. The company focuses on addressing unmet needs for patients with conditions stemming from immuno-inflammatory responses. Aclaris is actively involved in a range of projects, emphasizing innovation in the treatment of skin diseases and hair loss, among other health concerns. Their objectives include advancing their pipeline products through clinical trials with the goal of achieving market approval and creating effective treatments that improve patients' quality of life. Through rigorous research and development efforts, Aclaris aims to bring transformative therapies to the market, targeting conditions with significant patient impact.

Resumo

Public USParticipação acionária
2012Ano de fundação
89Funcionários
Pennsylvania, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Aclaris Therapeutics

  • ATI-450, an oral MK2 inhibitor for treating rheumatoid arthritis.
  • A-101 45% Topical Solution for common warts (verruca vulgaris).
  • ATI-1777, an investigational soft JAK 1/3 inhibitor applied topically for atopic dermatitis.
  • ATI-2138, an oral ITK inhibitor for T-cell mediated diseases, including psoriasis.

equipe executiva do Aclaris Therapeutics

  • Neal S. WalkerCo-Founder, CEO & Chairman
  • Hugh M. DavisPresident, COO & Director
  • Kevin BalthaserChief Financial Officer
  • James LoeropChief Business Officer
  • Roland KolbeckChief Scientific Officer
  • William C. RobertsSenior Vice President of Corporate Communications & Investor Relations
  • Matthew RothmanGeneral Counsel & Corporate Secretary
  • Steve TuckerExecutive Vice President of Project Leadership
  • Jesse W. HallChief Medical Officer
  • Nina SamraSenior Vice President of Clinical Operations

Principais indicadores financeiros

Resultados divulgados pela Aclaris Therapeutics, em USD.

Cap. de mercado
557,9 mi
Receita (TTM)
8,2 mi
P/L
—
LPA (diluído, TTM)
-0.6
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Aclaris Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
7,8 mi-76,4 mi-64,9 mi
18,7 mi-141,9 mi-132,1 mi
31,2 mi-97,4 mi-88,5 mi
29,8 mi-89,9 mi-86,9 mi